Nulecit Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Hypersensitivity reactions have been reported with injectable iron products. See PRECAUTIONS.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.


NulecitTM (sodium ferric gluconate complex in sucrose injection) is indicated for treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older undergoing chronic hemodialysis who are receiving supplemental epoetin therapy.


There is currently no drug history available for this drug.

Other Information

NulecitTM (sodium ferric gluconate complex in sucrose injection) is a stable macromolecular complex with an apparent molecular weight on gel chromatography of 289,000 to 440,000 daltons. The macromolecular complex is negatively charged at alkaline pH and is present in solution with sodium cations. The product has a deep red color indicative of ferric oxide linkages.

The structural formula is considered to be [NaFe2O3(C6H11O7)(C12H22O11)5]n≈200.

Each vial of 5 mL of NulecitTM for intravenous injection contains 62.5 mg (12.5 mg/mL) of elemental iron as the sodium salt of a ferric ion carbohydrate complex in an alkaline aqueous solution with approximately 20% sucrose w/v (195 mg/mL) in water for injection, pH 7.7 to 9.7.

Each mL contains 9 mg of benzyl alcohol as an inactive ingredient.

Therapeutic Class: Hematinic

Nulecit Manufacturers

  • Watson Pharma, Inc.
    Nulecit (Sodium Ferric Gluconate Complex) Injection [Watson Pharma, Inc.]

Login To Your Free Account